Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jounce Therapeutics Inc (JNCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,028
  • Shares Outstanding, K 32,700
  • Annual Sales, $ 71,640 K
  • Annual Income, $ -16,440 K
  • 36-Month Beta 3.81
  • Price/Sales 2.04
  • Price/Cash Flow N/A
  • Price/Book 1.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.35
  • Number of Estimates 6
  • High Estimate -0.23
  • Low Estimate -0.46
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -2.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.66 +36.84%
on 12/26/18
5.00 -27.20%
on 01/11/19
+0.77 (+26.83%)
since 12/21/18
3-Month
2.66 +36.84%
on 12/26/18
5.55 -34.41%
on 11/07/18
-1.72 (-32.09%)
since 10/22/18
52-Week
2.66 +36.84%
on 12/26/18
29.25 -87.56%
on 03/13/18
-18.58 (-83.62%)
since 01/22/18

Most Recent Stories

More News
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that the company completed...

JNCE : 3.64 (-4.21%)
Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced...

JNCE : 3.64 (-4.21%)
JPM : 102.94 (-1.58%)
Report: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Matrix Service Company (NASDAQ:MTRX),...

OXFD : 14.46 (-2.82%)
BGNE : 136.29 (-4.88%)
JNCE : 3.64 (-4.21%)
MTRX : 20.18 (-1.51%)
NH : 0.63 (-10.00%)
ESTE : 6.22 (-6.18%)
Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Tops Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 32.35% and 13.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the...

JNCE : 3.64 (-4.21%)
Jounce Therapeutics Reports Third Quarter 2018 Financial Results

- Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab and in combination with pembrolizumab, on track -

JNCE : 3.64 (-4.21%)
Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for

Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

JNCE : 3.64 (-4.21%)
New Research Coverage Highlights Himax Technologies, Corporacion America Airports S.A, Tecnoglass, Jounce Therapeutics, Hollysys Automation Technologies, and Obsidian Energy -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Himax Technologies, Inc....

CAAP : 6.50 (unch)
OBE : 0.44 (-10.86%)
JNCE : 3.64 (-4.21%)
HOLI : 21.03 (-0.61%)
HIMX : 3.58 (-2.45%)
TGLS : 8.45 (-0.59%)
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that its scientific...

JNCE : 3.64 (-4.21%)
Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Hugh Cole, chief...

JNCE : 3.64 (-4.21%)
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

ICONIC Target Enrollment Met Across Four Combination Cohorts

JNCE : 3.64 (-4.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNCE with:

Business Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator,...

See More

Key Turning Points

2nd Resistance Point 4.03
1st Resistance Point 3.83
Last Price 3.64
1st Support Level 3.52
2nd Support Level 3.41

See More

52-Week High 29.25
Fibonacci 61.8% 19.09
Fibonacci 50% 15.95
Fibonacci 38.2% 12.82
Last Price 3.64
52-Week Low 2.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar